A STUDY ON THE TREATMENT OUTCOME OF VARIOUS MANAGEMENT REGIMENS FOR LOCALLY ADVANCED CARCINOMA BREAST CANCER

Dr Ranvijay kumar, Dr N P Narain

Abstract


Background- Breast cancer is the commonest malignant disease among women in the Western world accounting for
1/5th (18%) of all cancers in women. Every year about one million women and several thousand men are diagnosed with
breast cancer worldwide.
Methods and materials- The study was carried out in the Departments of General Surgery and Radiotherapy, Patna Medical college& Hospital,
Patna between Sep 2012 and Oct 2014
Results- The median age was 45 years. Infiltrating ductal carcinoma was found in 86% cases. Modifies radical mastectomy was the commonest
surgery done post NACT (87.2%). Hormonal therapy showed relapse free survival in 81 percent cases. 82 percent relapse free survival was noted
in patients whose treatment regimen was a combination of NACT, surgery and radiotherapy.
Conclusion- Early confirmation of diagnosis, staging and metastatic work up is important. The whole treatment regimen is a multidisciplinary
approach consisting of surgeon, pathologist, oncologist and radiation oncologist. All cases should be treated aggressively.


Keywords


Mastectomy, Locally advanced breast cancer, Radiotherapy, Chemotherapy

Full Text:

PDF

References


- Aebi S, Davidson T, Gruber G, Castiglione M on behalf of the ESMO Guidelines Working Group. ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology (2010; 21 (5): 9–14)

- Agarwal G, Pradeep PV, Aggarwal V, Yip CH, Cheung PS. Spectrum of breast cancer in Asian women. World J Surg 2007; 31: 1031-4. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer (2010, 347-76)

- A. K. Garg, J. L. Oh, M. J. Oswald et al., “Effect of postmastectomy radiotherapy in patients <35 years old with stage II-III breast cancer treated with doxorubicin-based neoadjuvant chemotherapy and mastectomy,” International Journal of Radiation Oncology Biology Physics, vol. 69, no. 5, pp. (1478–1483, 2007)

- Anderson BO, Jakesz R. Breast cancer issues in developing countries: an overview of the breast health global initiative. World J Surg (2008; 32: 2579-85)

- Anonymous.Breast cancer in developing countries. Lancet (2009; 374: 1567)

- Bartelink H, Ruben RD, et al. Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: A European Organization for Research and Treatment of Cancer Randomized Phase III Trial. J ClinOncol (1997;15:207)

- Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J ClinOncol (2003; 21: 4165-4174)

- Aebi S, Davidson T, Gruber G, Castiglione M on behalf of the ESMO Guidelines Working Group. ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology (2010; 21 (5): 9–14)

- Agarwal G, Pradeep PV, Aggarwal V, Yip CH, Cheung PS. Spectrum of breast cancer in Asian women. World J Surg 2007; 31: 1031-4. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer (2010, 347-76)

- A. K. Garg, J. L. Oh, M. J. Oswald et al., “Effect of postmastectomy radiotherapy in patients <35 years old with stage II-III breast cancer treated with doxorubicin-based neoadjuvant chemotherapy and mastectomy,” International Journal of Radiation Oncology Biology Physics, vol. 69, no. 5, pp. (1478–1483, 2007)

- Anderson BO, Jakesz R. Breast cancer issues in developing countries: an overview of the breast health global initiative. World J Surg (2008; 32: 2579-85)

- Anonymous.Breast cancer in developing countries. Lancet (2009; 374: 1567)

- Bartelink H, Ruben RD, et al. Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: A European Organization for Research and Treatment of Cancer Randomized Phase III Trial. J ClinOncol (1997;15:207)

- Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J ClinOncol (2003; 21: 4165-4174)

- Bhattacharyya T, Sharma SC, Yadav BS, Singh R, Singh G. Outcome of neoadjuvant chemotherapy in locally advanced breast cancer: A tertiary care centre experience. Indian J Med PaediatrOncol (2014;35:215-2)

- Bloom H.J. and Richardson W.W. Histological grading and prognosis in breast cancer. Br. J. Cancer (1957; 11: 359-377)

- Bonadonna G, Valagussa P, Brambilla C et al. “Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute,” Journal of Clinical Oncology (1998; 16(1): 93–100)

- Bray F, McCarron P, Parkin DM, et al. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res (2004; 6: 229-23).

- Buchholz TA, Hunt KK, Whitman GJ, et al. Neoadjuvant chemotherapy for breast carcinoma: Multidisciplinary considerations of benefits and risks. Cancer (2003; 98: 1150-1160)

- Aebi S, Davidson T, Gruber G, Castiglione M on behalf of the ESMO Guidelines Working Group. ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology (2010; 21 (5): 9–14)

- Agarwal G, Pradeep PV, Aggarwal V, Yip CH, Cheung PS. Spectrum of breast cancer in Asian women. World J Surg 2007; 31: 1031-4. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer (2010, 347-76)

- A. K. Garg, J. L. Oh, M. J. Oswald et al., “Effect of postmastectomy radiotherapy in patients <35 years old with stage II-III breast cancer treated with doxorubicin-based neoadjuvant chemotherapy and mastectomy,” International Journal of Radiation Oncology Biology Physics, vol. 69, no. 5, pp. (1478–1483, 2007)

- Anderson BO, Jakesz R. Breast cancer issues in developing countries: an overview of the breast health global initiative. World J Surg (2008; 32: 2579-85)

- Anonymous.Breast cancer in developing countries. Lancet (2009; 374: 1567)

- Bartelink H, Ruben RD, et al. Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: A European Organization for Research and Treatment of Cancer Randomized Phase III Trial. J ClinOncol (1997;15:207)

- Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J ClinOncol (2003; 21: 4165-4174)

- Bhattacharyya T, Sharma SC, Yadav BS, Singh R, Singh G. Outcome of neoadjuvant chemotherapy in locally advanced breast cancer: A tertiary care centre experience. Indian J Med PaediatrOncol (2014;35:215-2)

- Bloom H.J. and Richardson W.W. Histological grading and prognosis in breast cancer. Br. J. Cancer (1957; 11: 359-377)

- Bonadonna G, Valagussa P, Brambilla C et al. “Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute,” Journal of Clinical Oncology (1998; 16(1): 93–100)

- Bray F, McCarron P, Parkin DM, et al. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res (2004; 6: 229-23).

- Buchholz TA, Hunt KK, Whitman GJ, et al. Neoadjuvant chemotherapy for breast carcinoma: Multidisciplinary considerations of benefits and risks. Cancer (2003; 98: 1150-1160)

- Chen LC, Weiss NS, Newcomb P, et al. Hormone replacement therapy in relation to breast cancer. JAMA (2002; 287: 734–74).

- Clarke M, Collins R, Darby S et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005; 366: 2087–210).


Refbacks

  • There are currently no refbacks.